RP
Royalty Pharma
RPRX · NASDAQ
$58.75 -2.73% (-$1.65)
1M -0.79%
Market Cap $26.0B
P/E Ratio 31.94x
Div. Yield 1.57%
ROE 12.25%
Bulios Fair Price
$40.49
31.1% downside
Current Price
$58.75
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RPRX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
46 /100
Fair P/E 31.94x
EV/EBITDA 19.93x
P/S 10.27x
Growth
57 /100
Stable EPS growth 162.07%
Rev. growth 2.06%
FCF growth 5.11%
Profitability
100 /100
Strong Gross margin 89.38%
Net margin 32.15%
Op. margin 62.34%
Quality
43 /100
Average ROIC 8.08%
ROE 12.25%
ROA 4.11%
Debt
36 /100
Moderate Debt/Equity 1.31x
Current ratio 1.29x
Int. coverage 4.74x
Stability
59 /100
Moderate Beta 0.43x
Rev. volatility 5.21%
EPS volatility 1,411.73%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RPRX
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Pablo Legorreta
Employees
100
Headquarters
New York
Upcoming events
04 NOV
Earnings
Upcoming earnings report